1750-42-1

Basic information

• Product Name: 3-Aminoisoxazole
• Synonyms: ISOXAZOL-3-AMINE;3-AMINOISOXAZOLE;3-Aminoisoxazole 95%;3-Amineisoxazole;3-Aminoisoxazole,95%;3-Aminoisoxazole3-Isoxazolamine;3-isoxazolamine(SALTDATA: FREE);3-Isoxazolamine
• CAS NO: 1750-42-1
• Molecular Formula: C₃H₄N₂O
• Molecular Weight: 84.08
• EINECS: 1592732-453-0
• Product Categories: Amines;Oxazoles, Isoxazoles & Benzoxazoles;Oxazole&Isoxazole;Oxazoles, Isoxazoles & Benzoxazoles;Building Blocks;Heterocyclic Building Blocks;Isoxazoles;Pyridines
• Mol File: 1750-42-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 148-150 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
• Boiling Point: 226-228 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear yellow/Liquid
• Density: 1.138 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000559mmHg at 25°C
• Refractive Index: n20/D 1.511(lit.)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.27±0.10(Predicted)
• CAS DataBase Reference: 3-Aminoisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Aminoisoxazole(1750-42-1)
• EPA Substance Registry System: 3-Aminoisoxazole(1750-42-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-37/38-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1750-42-1(Hazardous Substances Data)

Usage

Chemical Properties

Clear yellowish liquid

Uses

3-Aminoisoxazole (isoxazol-3-amine) may be used in the following studies:As a reagent in the synthesis of N-(4-(N-isoxazol-3-ylsulfamoyl)phenyl)acetamide.As a starting material in the synthesis of N-(isoxazol-3-yl)-N′-(carbomethoxy)thiourea.As a starting material in the synthesis of (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxy-iminoacetic acid, a side-chain of the fourth generation of cephem antibiotics.

General Description

3-Aminoisoxazole (isoxazol-3-amine) is a 3-substituted isoxazole derivative. It is a structural isomer of 5-aminoisoxazole.

InChI:InChI=1/C7H6N2O/c8-7-5-3-1-2-4-6(5)10-9-7/h1-4H,(H2,8,9)

Upstream product

• 7341-96-0 2-propynamide 
• 4554-16-9 2,3-dibromopropionitrile 
• 2601-89-0 2,3-dichloropropionitrile 
• 127-07-1 N-hydroxyurea 
• 288-14-2 ISOXAZOLE 

Downstream Products

• 1188284-39-0 3-(1-(2,4-difluorophenyl)-7-ethyl-6-oxo-6,7-dihydro-1H-pyrazolo[4,3-b]pyrazin-5-yl)-5-fluoro-N-(isoxazol-3-yl)-4-methylbenzamide 
• 444791-39-3 phenyl N-(isoxazol-3-yl)carbamate 
• 1124212-08-3 N-tert-butyl-3-((4-(4-(3-isoxazol-3-ylureido)benzoyl)piperazin-1-yl)methyl)benzamide 
• 1033779-87-1 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-isoxazol-3-yl-acetamide 
• 861877-51-2 AMG0309 

Relevant articles and documents

Preparation method of 3-aminoisoxazole

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of 3aminoisoxazole, which comprises the following steps: (1) preparing 2, 3dichloropropionitrile: adding acrylonitrile, N, Ndimethylformamide and pyridine into a reaction vessel, cooling to 5-15 DEG C, introducing chlorine into the reaction vessel, and keeping the reaction temperature at 1020 DEG C; controlling the temperature to be 15-25 DEG C and stirring for 5 hours after the chlorine gas is introduced; blowing excessive chlorine until the reaction liquid is yellowish or colorless andtransparent to obtain 2, 3dichloropropionitrile; and (2) preparation of 3amino isoxazole: under an alkaline condition, synthesizing 3amino isoxazole by taking hydroxyurea and 2, 3dichloropropionitrile as raw materials and N, Ndimethylformamide as a catalyst. The preparation method is used for solving the technical problems of extremely easy material punching and high process risk caused by the adoption of a 2, 3dibromopropionitrile intermediate in the existing 3amino isoxazole preparation.

Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.